Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Moderna
Historiska aktiekurser
Aktuell aktiekurs	US$46.88
52 veckors högsta	US$59.55
52 veckors lägsta	US$22.28
Beta	1.06
1 månads förändring	-7.59%
3 månaders förändring	-6.78%
1 års förändring	78.52%
3 års förändring	-62.86%
5 års förändring	-74.66%
Förändring sedan börsintroduktionen	152.04%

Senaste nyheter och uppdateringar

Uppdatering av berättelse • May 13

MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome

Narrative Update on Moderna Analysts have collectively raised their Moderna price targets by low to mid single digit dollar amounts, citing updated models that reflect recent litigation settlements, FDA progress on the flu vaccine, and oncology pipeline developments. Together, these factors support a lower fair value estimate of $66.29, a slightly higher discount rate of 7.21%, adjusted revenue growth expectations of 52.59%, a profit margin of 4.12%, and a future P/E assumption of 107.40x.

Seeking Alpha • May 12

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

Summary Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets. RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and strategic pivots. Combination mRNA vaccines like mCOMBRIAX offer regulatory progress but commercial success remains uncertain amid persistent vaccine fatigue. Personalized cancer vaccines may leverage mRNA speed but face margin, scalability, and regulatory hurdles, limiting their financial upside for MRNA. Read the full article on Seeking Alpha

Recent updates

Uppdatering av berättelse • May 13

MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome

Seeking Alpha • May 12

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

Uppdatering av berättelse • Apr 27

MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside

Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.

Uppdatering av berättelse • Apr 13

MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside

Analysts have nudged Moderna's average price target higher by $5, reflecting a mix of renewed confidence in the company's vaccine pipeline after the FDA's reconsideration of its flu shot application and reduced litigation overhang following recent settlement developments. Analyst Commentary Recent research on Moderna clusters around two main themes for you to watch closely: valuation reset around the vaccine pipeline and lingering legal and execution risks tied to the COVID and flu franchises.

Uppdatering av berättelse • Mar 30

MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside

Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.

Uppdatering av berättelse • Mar 16

MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside

Analysts have trimmed Moderna's implied fair value from $15.00 to $12.00 as they factor in a higher discount rate, more moderate profit margins and updated views on revenue growth following recent litigation settlements and regulatory updates. Analyst Commentary Street research around Moderna centers on two themes that matter for you as an investor: the clean-up of legal overhangs and how much confidence to place in the broader vaccine and oncology pipeline.

Uppdatering av berättelse • Mar 02

MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision

Our fair value estimate for Moderna has inched up by about $1.65 per share to $91.97 as analysts update their models around higher projected product sales, a more constructive FDA review path for the mRNA-1010 flu vaccine with an August 5 PDUFA date, and refreshed views on the broader late stage pipeline including oncology. Analyst Commentary Street research on Moderna has leaned more constructive around the updated regulatory path for flu vaccine mRNA-1010, the broader late stage pipeline, and recent quarterly disclosures.

Analysartikel • Feb 17

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest annual results with some very strong...

Uppdatering av berättelse • Feb 16

MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes

Analysts have nudged their average price target for Moderna higher by about $3, reflecting updated views on long term revenue potential, profit margins and a higher future P/E multiple following recent research on COVID demand, the broader vaccine pipeline and legal outcomes. Analyst Commentary Recent Street research on Moderna highlights a mix of caution and growing optimism, with several bullish analysts adjusting their models after company updates, legal developments and new financing disclosures.

Analysartikel • Feb 02

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Despite an already strong run, Moderna, Inc. ( NASDAQ:MRNA ) shares have been powering on, with a gain of 43% in the...

Uppdatering av berättelse • Feb 01

MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside

The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple. Analyst Commentary Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern.

Uppdatering av berättelse • Jan 18

MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential

Narrative update We trim our analyst price target for Moderna from about US$121 to roughly US$87 as analysts factor in lower profit margin expectations, a higher discount rate, cautious views on COVID-related revenue visibility, and a more binary risk profile around key late stage vaccine data, even as some models reflect higher revenue growth assumptions and updated financing terms. Analyst Commentary Recent Street research on Moderna points to a mixed backdrop, with several firms reaffirming cautious stances while still recognizing specific areas where execution and funding choices could support long term value creation.

Uppdatering av berättelse • Jan 04

MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation

Analysts have modestly lifted their price targets on Moderna, with recent revisions such as $15 to $18, $16 to $17, and $32 to $30. These changes collectively reflect slightly improved conviction in the company’s long term revenue growth, gross margin expansion, and strengthened liquidity following new Ares financing, despite ongoing profitability and litigation risks.

Uppdatering av berättelse • Dec 21

MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks

Analysts have modestly raised their price target on Moderna to align with a slightly higher fair value estimate of about $36.75, citing incremental improvements in long term revenue growth and profitability assumptions supported by recent Investor and Analyst Day updates, revised 2026 to 2028 guidance, and Ares financing. Analyst Commentary Recent Street research reflects a cautious but incrementally more constructive stance toward Moderna, with several firms refining their models following Investor and Analyst Day presentations and the announcement of new financing.

Analysartikel • Dec 19

There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 28% share price jump in the last...

Uppdatering av berättelse • Dec 07

MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk

Analysts have modestly lowered their price target on Moderna to about $35.78 from $37.32 per share, reflecting slightly softer long term growth and valuation assumptions. This comes even as recent Investor and Analyst Day updates, new debt financing and evolving oncology data support a more stable cash outlook and gradual margin improvement.

Uppdatering av berättelse • Nov 23

MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts

Analysts have revised their fair value estimate for Moderna down from approximately $40.30 to $37.32. They cited the company’s updated revenue growth projections and cost outlook, despite improvements in profit margins and continued progress across its commercial and research pipelines.

Uppdatering av berättelse • Nov 07

MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties

Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.

Uppdatering av berättelse • Oct 23

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Moderna’s analyst price target has been revised downward from $44.25 to $40.30. Analysts cite lower projected revenue growth along with persistent regulatory and profitability challenges, which have been reflected in recent industry commentary.

Uppdatering av berättelse • Sep 04

Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential

Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.

Analysartikel • Jul 18

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 26% share price jump in the last...

Ny berättelse • May 02

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and

Seeking Alpha • Apr 22

More Downside For Moderna Before The Breakthrough

Summary Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires investor patience, with key vaccines in Phase 3 trials but regulatory approvals potentially years away. Financials are sound enough to support long term research, with a significant cash buffer, but oncology research faces regulatory and technical challenges. Shares are likely to go down before any uptrend (2-3 years horizon). Read the full article on Seeking Alpha

Seeking Alpha • Mar 31

FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)

Summary Moderna's stock dropped over 10% after the FDA's Dr. Peter Marks resigned, signaling potential increased regulatory scrutiny on vaccines. Moderna's financial health remains strong, with ~$9 billion in cash and investments, but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's revenue outlook. Given the negative public perception of mRNA technology and regulatory risks, I downgrade MRNA to "Hold" until more clarity emerges. Read the full article on Seeking Alpha

Seeking Alpha • Mar 06

Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out

Summary Moderna, Inc.'s stock surged 16% yesterday after a German court ruled Pfizer and BioNTech may have violated Moderna's COVID-19 vaccine patent, potentially leading to compensation. Despite the ruling, Pfizer and BioNTech will appeal, while previous court decisions have invalidated related patents, complicating Moderna's legal victory. MRNA's business struggles post-pandemic, with declining revenues and few new products, have made litigation a potentially critical revenue source, which I'd call a red flag. The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products since 2022, instead of one, it's unlikely yesterday's news would have moved its share price, but this reflects the new reality of messenger-RNA, a technology that hasn't lived up to the hype — yet. Read the full article on Seeking Alpha

Seeking Alpha • Feb 14

Moderna, Inc.: Working Hard But Competition Is Working Harder

Summary MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition. Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Read the full article on Seeking Alpha

Ny berättelse • Feb 09

Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks

Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.

Seeking Alpha • Feb 03

Moderna: The Good News Isn't Enough

Summary I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock. I argue why I don't think anything has changed materially, reinforcing my SELL rating. Despite cost-cutting measures, I am concerned that reducing R&D will hurt Moderna's research capabilities, preferring cuts in SG&A instead. Read the full article on Seeking Alpha

Seeking Alpha • Jan 10

Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)

Summary Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential. The company's cost-cutting measures may hinder innovation, but rising COVID cases and bird flu risks could uniquely benefit Moderna if a pandemic occurs. Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads significantly. With only a 5% chance of a bird flu pandemic, I believe Moderna is a hold, awaiting further developments on the bird flu's virality. Read the full article on Seeking Alpha

Seeking Alpha • Dec 31

Moderna: 2025 Contrarian Play

Summary Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses. Investors should consider buying the beaten-down stock around $40, anticipating higher sales and multiple big approvals in the coming years. Read the full article on Seeking Alpha

Seeking Alpha • Dec 18

Moderna: Cutting Costs Might Not Be Enough

Summary Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. MRNA has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. Read the full article on Seeking Alpha

Seeking Alpha • Nov 22

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Summary Moderna, Inc.'s stock has plummeted over 75% in 2024, driven by disappointing earnings, reduced revenue forecasts, and now the threat of a vaccine skeptic, RFK Jr.'s potential confirmation to lead HHS. Despite two commercialized vaccines and positive Phase 3 results for others, Moderna faces uncertainty in achieving profitability before 2028, with significant R&D expenses and competitive pressures. The private COVID-19 vaccine market is considered stable but limited, and the RSV vaccine faces competition from GSK and Pfizer, and likely restriction to a once-every 3-year dose. A potential acquisition by a Big Pharma like Merck could bring fresh R&D perspectives, but Moderna may need to consider further program cuts to achieve profitability in a shorter time-frame. Read the full article on Seeking Alpha

Seeking Alpha • Oct 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Summary GSK's lawsuit against Moderna over lipid nanoparticle technology could severely impact Moderna's revenue from Spikevax and mResvia, and delay their breakeven point. The lawsuit adds uncertainty to MRNA's already declining stock, increasing short-selling activity and potentially leading to prolonged negative headlines. Despite the legal risks, I plan to trade MRNA, looking for a reversion play if the ticker breaks its downtrend with elevated volume. I am lowering my MRNA conviction level from 3 to 2 out of 5 and moving it to the speculative “Bio Boom” portfolio. Read the full article on Seeking Alpha

Seeking Alpha • Sep 20

Moderna: Still Bullish View

Summary Moderna's stock has fallen due to the weak management revenue guidance, but I remain positive about its long-term potential. Key developments include the next-gen COVID-19 vaccine, the RSV vaccine, and promising pipeline drugs like the cytomegalovirus and cancer vaccines. Management's 2024 revenue guidance is conservative. I expect Moderna to outperform it. My fair valuation of Moderna stock was adjusted to $149. Read the full article on Seeking Alpha

Seeking Alpha • Sep 12

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Summary Moderna, Inc. plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs, leading to a pre-market stock drop of over 13%. Despite pledging 10 product approvals by 2027, falling COVID-19 vaccine sales and increased competition cast doubt on achieving a >25% CAGR. MRNA's financial outlook remains bleak, with expected losses through 2024 and speculative rather than concrete market opportunities for its late-stage pipeline assets. Short-to-medium term downside is likely, though long-term potential remains if new vaccines, like a COVID/flu combo or CMV, succeed. Read the full article on Seeking Alpha

Seeking Alpha • Aug 26

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Summary Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech's combination vaccine faced setbacks, giving Moderna a potential advantage in the market. The market for Moderna's RSV vaccine may be limited due to updated CDC recommendations. Moderna's oncology pipeline, including mRNA-4157/V940, shows promise but remains in the early stages. Despite short-term challenges, Moderna's combination vaccine could lead to long-term market outperformance. Read the full article on Seeking Alpha

Aktieägarnas avkastning

	MRNA	US Biotechs	US Marknad
7D	-4.4%	1.2%	1.1%
1Y	78.5%	34.6%	28.7%

Avkastning vs industri: MRNA översteg US Biotechs branschen som gav 34.6 % under det senaste året.

Avkastning vs Marknaden: MRNA översteg US marknaden som gav 28.7 % under det senaste året.

Prisvolatilitet

Is MRNA's price volatile compared to industry and market?
MRNA volatility
MRNA Average Weekly Movement	9.0%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

Stabil aktiekurs: MRNA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: MRNA s veckovolatilitet ( 9% ) har varit stabil under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
2010	4,700	Stéphane Bancel	www.modernatx.com

Moderna, Inc. är ett bioteknikföretag som tillhandahåller läkemedel med budbärar-RNA i USA, Europa och internationellt. Företagets andningsvacciner omfattar spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, säsongsinfluensa, kombinationsvaccin och pandemiskt influensavaccin; latenta vacciner omfattar cytomegalovirus-, epstein-barr-virus- och humant immunbristvirusvacciner; enteriska virus omfattar norovirus; folkhälsovacciner omfattar zika-, nipah- och mpox-vacciner; och vacciner mot bakteriesjukdomar, såsom lyme-vacciner. Företaget tillhandahåller också onkologiska läkemedel, t.ex. intismeran autogene, cancer antigen therapy, t-cell engager och cell therapy enhancer, samt produkter för sällsynta sjukdomar, t.ex. propionsyra- och metylmalonsyrademi samt cystisk fibros.

Moderna, Inc. Sammanfattning av grunderna

Hur förhåller sig Moderna:s resultat och omsättning till dess börsvärde?
MRNA grundläggande statistik
Börsvärde	US$18.60b
Vinst(TTM)	-US$3.19b
Intäkter(TTM)	US$2.23b

8.4x

P/S-förhållande

-5.8x

P/E-förhållande

Är MRNA övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
MRNA resultaträkning (TTM)
Intäkter	US$2.23b
Kostnad för intäkter	US$3.78b
Bruttovinst	-US$1.55b
Övriga kostnader	US$1.64b
Intäkter	-US$3.19b

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)	-8.05
Bruttomarginal	-69.89%
Nettovinstmarginal	-143.55%
Skuld/egenkapitalförhållande	8.0%

Hur har MRNA utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/24 16:28
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Moderna, Inc. bevakas av 45 analytiker. 22 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
null null	Argus Research Company
Eliana Merle	Barclays
Huidong Wang	Barclays

Moderna (MRNA) Aktievy

Belöningar

Riskanalys

Analyst Price Targets

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Inflated Valuation Will Choke Revenue Amid Tighter Global Scrutiny

Global Preventative Medicine Demand And mRNA Pipelines Will Transform Healthcare

Top Community Narratives

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Top Community Narratives

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Top Analyst Narratives

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Inflated Valuation Will Choke Revenue Amid Tighter Global Scrutiny

Global Preventative Medicine Demand And mRNA Pipelines Will Transform Healthcare

Moderna, Inc. Konkurrenter

BioNTech

Incyte

Biogen

United Therapeutics

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Moderna mRNA Flu Vaccine Shows Strong Phase 3 Results With FDA Decision Expected in 2026

President notifies of intention to sell stock

MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.3% to US$41.42

Recent updates

Moderna mRNA Flu Vaccine Shows Strong Phase 3 Results With FDA Decision Expected in 2026

President notifies of intention to sell stock

MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.3% to US$41.42

Consensus EPS estimates fall by 10%

MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside

Moderna, Inc. to Report Q1, 2026 Results on May 01, 2026

MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside

MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside

Moderna, Inc., Annual General Meeting, May 06, 2026

MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement with Moderna

MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision

President notifies of intention to sell stock

Price target increased by 7.2% to US$41.60

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010

Arbutus Biopharma Corporation Announces Court Ruling on Patent Infringement Dispute over Lipid Nanoparticle Vaccine Technology

Now 20% overvalued after recent price rise

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside

Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026

Moderna, Inc. to Report Q4, 2025 Results on Feb 13, 2026

MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential

New minor risk - Share price stability

MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation

MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks

There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

CEO & Director exercised options to buy US$21m worth of stock.

Insider exercised options and sold US$582k worth of stock

Insider exercised options and sold US$582k worth of stock

MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk

Price target decreased by 10% to US$35.78

MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts

Consensus estimates of losses per share improve by 18%

Moderna, Inc. Lowers Earnings Guidance for Full Year 2025

MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 9.0% to US$40.30

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Moderna, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Price target increased by 15% to US$52.05

Moderna, Inc.(NasdaqGS:MRNA) dropped from FTSE All-World Index (USD)

Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Value Index